Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Goldschmidt H, Mai EK, Dürig J, Scheid C, Weisel KC, Kunz C, Bertsch U, Hielscher T, Merz M, Munder M, Lindemann HW, Hügle-Dörr B, Tichy D, Giesen N, Hose D, Seckinger A, Huhn S, Luntz S, Jauch A, Elmaagacli A, Rabold B, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab MS, Blau IW, Hänel M, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG). Goldschmidt H, et al. Among authors: elmaagacli a. Leukemia. 2020 Jul;34(7):1853-1865. doi: 10.1038/s41375-020-0724-1. Epub 2020 Feb 7. Leukemia. 2020. PMID: 32034285 Clinical Trial.
Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy.
Elmaagacli AH, Salwender H, Jehn C, Dahmash F, Singh A, Wilson O, Pannenbeckers M, Niggemann C, Vierbuchen M. Elmaagacli AH, et al. Leuk Lymphoma. 2019 Dec;60(13):3335-3338. doi: 10.1080/10428194.2019.1623887. Epub 2019 Jun 4. Leuk Lymphoma. 2019. PMID: 31164030 No abstract available.
Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.
Lorentino F, Labopin M, Ciceri F, Vago L, Fleischhauer K, Afanasyev B, Kröger N, Cornelissen JJ, Lovira M, Meijer E, Vitek A, Elmaagacli A, Blaise D, Ruggeri A, Chabannon C, Nagler A, Mohty M; Acute Leukemia Working Party (ALWP) and Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT). Lorentino F, et al. Among authors: elmaagacli a. Leukemia. 2021 Feb;35(2):585-594. doi: 10.1038/s41375-020-0863-4. Epub 2020 May 14. Leukemia. 2021. PMID: 32409688
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Mai EK, Miah K, Bertsch U, Dürig J, Scheid C, Weisel KC, Kunz C, Munder M, Lindemann HW, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Hänel M, Benner A, Salwender HJ, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG). Mai EK, et al. Among authors: elmaagacli a. Leukemia. 2021 Mar;35(3):809-822. doi: 10.1038/s41375-020-0976-9. Epub 2020 Jul 20. Leukemia. 2021. PMID: 32684633 Free PMC article. Clinical Trial.
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
Salwender H, Elmaagacli A, Merz M, Miah K, Benner A, Haenel M, Jehn C, Mai EK, Bertsch U, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Raab MS, Luntz SP, Besemer B, Munder M, Brossart P, Fuhrmann S, Lindemann HW, Weisel K, Duerig J, Goldschmidt H. Salwender H, et al. Among authors: elmaagacli a. Leukemia. 2021 Oct;35(10):3007-3011. doi: 10.1038/s41375-021-01298-y. Epub 2021 May 24. Leukemia. 2021. PMID: 34031532 Clinical Trial. No abstract available.
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
Klein EM, Tichy D, Salwender HJ, Mai EK, Duerig J, Weisel KC, Benner A, Bertsch U, Akhavanpoor M, Besemer B, Munder M, Lindemann HW, Hose D, Seckinger A, Luntz S, Jauch A, Elmaagacli A, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Raab MS, Blau IW, Haenel M, Scheid C, Goldschmidt H, On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg. Klein EM, et al. Among authors: elmaagacli a. Cancers (Basel). 2021 Sep 28;13(19):4856. doi: 10.3390/cancers13194856. Cancers (Basel). 2021. PMID: 34638344 Free PMC article.
112 results